Objective:
Introduction
It has long been known that the use of psychostimulants (e.g., methylphenidate [MPH] , dextroamphetamine, and d-l-amphetamine) is the treatment of choice in normally developing children with attention deficit hyperactivity disorder (ADHD) (Barkley et al. 1999; Wilens and Spencer 2000) . However, the earliest studies of psychostimulants in patients with mental retardation were often negative. Gadow (1985) , who reviewed this literature, noted that presence
Study 1.
The participants were 32 New Zealand children and adolescents attending special schools, special classes, or special resource classes for children with mental retardation. Age ranged from 4 to 17 years (mean = 10.1, SD = 3.1 years). IQs ranged from unmeasurable to 90 (mean = 52.8, SD = 20.3). There were 27 boys (84.4%) and 5 girls (15.6%). Ethnicity was as follows: Caucasian (n = 22, 68.8%), New Zealand Maori (n = 6, 18.8%), and Pacific Islander (n = 4, 12.5%).
Entry criteria required each child to meet Diagnostic and Statistical Manual of Mental Disorders, third edition (DSM-III; American Psychiatric Association 1980) criteria for attention deficit disorder (ADD) (n = 29) or conduct disorder (CD) (n = 1) or both ADD and CD (n = 2). Rating scales completed by parents and teachers and a structured interview using the Diagnostic Interview Schedule for Parents (DISC-P) (Shaffer et al. 1989 , unpublished manuscript) along with a clinical interview supported the diagnosis. Twenty-four of the subjects met DSM-III criteria for attention deficit disorder with hyperactivity (ADD-H). Four were diagnosed as having attention deficit disorder without hyperactivity, and one had attention deficit disorder, residual type. Three participants had a conduct disorder, and one child had pervasive developmental disorder not otherwise specified (PDD-NOS) in addition to ADD-H. Other than conduct disorder, autistic disorder, and PDD-NOS, the participants were not screened for additional DSM disorders.
Study 2.
The subjects were 28 American children, aged 5 to 13 years (mean age = 8.8, SD = 2.6 years). There were 20 boys (66.7%) and 8 girls (33.3%). The children's IQs ranged from untestable (2 children) to 78, with a mean of 61.0. There were three African American and 25 Caucasian children in this group. Inclusionary criteria were the following: (a) IQ ≤ 80, (b) presence of severe inattention or hyperactivity as assessed on the CTRS (i.e., exceeding 90th percentile on the Inattention or Hyperactivity subscales relative to norms), (c) presence of severe inattention or motor excess as rated by parents on the Revised Behavior Problem Checklist (RBPC; Quay and Peterson 1987) (i.e., exceeding the 90th percentile on these subscales), (d) professional diagnosis of ADHD based on DSM-III-R criteria (American Psychiatric Association 1987), and (e) aged between 5 and 13 years. Exclusion criteria included the following: (a) motor handicap, (b) autism or symptoms of psychosis, (c) epilepsy, and (d) Down syndrome (excluded because Down syndrome was thought to be a possible contraindication for one of the two study drugs, fenfluramine).
Study 3.
The inclusionary and exclusionary criteria were the same as for study 2, with some minor exceptions. First, age extended from 5 to 14 years. Second, the upper limit for IQ was 84 rather than 80. Otherwise all criteria were identical. In all, 35 children participated. Five of these were dropped because of noncompliance with the protocol. There were 22 boys and 8 girls. Mean age was 7.7 years (SD = 2.5 years). There were 5 African American subjects (16.7%), 1 Hispanic (3.3%), 1 Asian (3.3%), 21 Caucasian (70.0%), and 2 (6.7%) with mixed ethnicity (African American and Caucasian). IQs extended from the basal score (36) to 84, with a mean of 61.8 (SD = 13.63). We did not attempt to do formal psychiatric diagnoses for comorbidity, but the participants' parents did complete the Stony Brook Checklist-3R (Gadow and Sprafkin 1987, unpublished manuscript) , a screening instrument based on DSM-III-R criteria. The numbers screened for each comorbid disorder were as follows: conduct disorder (n = 7), oppositional defiant disorder (n = 3), overanxious disorder (n = 2), and separation anxiety disorder (n = 6). Two of the children had PDD-NOS.
Combined sample.
When all three samples were combined, we had a pooled sample of 90 children, with an age range extending from 4 to 17 years (mean = 9.0, SD = 2.9 years). IQ ranged from untestable to 90, with a mean of 58.5 (SD = 16.1). Mental age extended from 1.9 to 9.9 years (mean = 4.9, SD = 1.87 years). There were 69 boys (76.7%) and 21 girls (23.3%). Ethnicity was as follows: African American (n = 8, 8.9%), Asian (n = 1, 1.1%), Caucasian (n = 68, 75.6%), Hispanic (n = 1, 1.1%), Maori (n = 6, 6.7%), Pacific Islander (n = 4, 4.4%), and mixed (African American and Caucasian) (n = 2, 2.2%). Almost all of the children were in special educational placements, usually in classrooms designated for children with mental retardation. Furthermore, although nine of these children currently tested above the mentally retarded range (i.e., above 75), most of these had at some previous time been found to have mental retardation as assessed on IQ and adaptive behavior scales (e.g., one child in Aman et al. 1993 ; five children in Aman et al. 1997) . After complete description of the study to the parents, written informed consent was obtained. A multitude of events (e.g., the winter blizzards of 1994 and failure of teachers to mail forms) and some outliers (see the Data Analysis section) caused some data loss. In addition, only about 70% of subjects could perform the cognitive tests. As a result, the mean sample size for the clinical (rating scale) measures was 84, for cardiovascular measures 85, and the mean sample size for the cognitive tests was 62.
Design
All three studies employed crossover designs, and all three included a double-blind comparison of placebo, MPH (0.40 mg/kg) given in the morning only, and another drug. This standardized dose of MPH was selected because previous studies in typically developing children suggested that the dose fell midway between an optimal dose for performance on a short-term memory task (i.e., 0.3 mg/kg) and behavior (i.e., around 0.70 mg/kg) Sleator 1973, 1977) . Not all attempts to replicate these dose response curves have been successful (see Richters et al. 1995) .
Study 1 was a comparison of placebo, MPH, and thioridazine (Mellaril, USA) given in divided daily doses of 1.75 mg/kg. Each drug condition was given for 3 weeks. Study 2 was a comparison of placebo, MPH, and fenfluramine (Pondimin, USA) given in divided daily doses of 1.50 mg/kg/day. All three conditions were given for 4 weeks each. Study 3 was a comparison of placebo, MPH, and three doses of fenfluramine (1.0, 1.5, 2.0 mg/kg/ day) given in divided daily doses. Each medication was given for 2 weeks. Studies 1 and 2 used Latin square designs to balance drug order and time; there were three drug orders for each study. Study 3 used two mirror-image Latin squares, and each drug condition appeared equally often at each possible time point.
Thus, all participants received placebo and the same dose of MPH, given in the same regimens (once daily, administered before going to school). The order of medication (placebo first, MPH second, and vice versa) was balanced, although sometimes comparator medicines were administered between them. Equal numbers of children received placebo first and MPH second and vice versa. There were no interactions in these studies between drug order and drug effect on any of the outcome variables showing a significant drug effect. On the last day of each drug period, all subjects were brought by their parents to the laboratory for standardized assessments, which included parent ratings, heart rate and blood pressure assessment, and evaluation of cognitive performance using computer-controlled equipment. These assessments were usually begun 60 to
Measures of drug change
With the exception of the Aberrant Behavior Checklist (ABC; Aman et al. 1985) , all variables described below were used in all three studies. The ABC was used only in studies 2 and 3.
Behavioral measures.
The children were rated by their teachers on the CTRS (Conners 1969 ) and the ABC (Aman et al. 1985) . The 39-item CTRS was developed by factor analysis with typically developing children; it has four subscales: Conduct Problem, Inattention, Tension/Anxiety, and Hyperactivity. Furthermore, we derived a score for the CASQ from the CTRS. The CASQ is a 10-item instrument, comprising items related to ADHD and emotionality, that has often been used in drug research (Aman and Pearson 1999; Goyette et al. 1978) . The ABC was developed by factor analysis with children and adults having mental retardation. Its five subscales are designated as: Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/ Noncompliance, and Inappropriate Speech.
Parents rated their children on the Revised Behavior Problem Checklist (RBPC), an 89-item instrument also developed by factor analysis with typically developing children (Quay and Peterson 1987) . Its six subscales were designated as follows: Conduct Problem, Socialized Aggression, Attention Problem, Anxiety/Withdrawal, Psychotic Behavior, and Motor Excess. The RBPC has frequently been used in clinical research, especially that involving conduct and aggressive disorders, but it has not been frequently used in drug research (Aman and Pearson 1999 ). Because we did not regard the Socialized Aggression subscale as relevant for many of our participants, we deleted the items from this subscale. Parents also rated their children on the CASQ and on the ABC described earlier.
Cardiovascular.
Each time the children visited the laboratory, their radial heart rate and blood pressure were monitored by a physician with the subject seated following a 5-minute period of rest.
Cognitive performance and activity level.
Each time the subject visited the laboratory, he or she was assessed on a cognitive battery that was mostly computer controlled. There is a body of psychometric data on all of the performance measures used. Each of the tests has adequate reliability, validity, and drug sensitivity to be a useful measure of treatment outcome (see Aman 1991) . The following tests were included.
Matching to Sample (MTS) task:
The MTS task was developed to assess memory in pigeons (Cumming and Berryman 1965) . We adapted it for use in children with low IQ. Our version involved the repeated presentation of three colors: red, yellow, and blue. One color was presented at the center-top of the screen. The subject then pressed the screen to indicate that he or she saw the stimulus. One second later, the colors red, yellow, and blue were displayed at the bottom of the screen. The child's job was to locate the color that matched that previously seen and to press that part of the screen. Each time the child got three consecutive trials in a row correct, the computer added 1.0 second to the delay between the test stimulus and the response stimuli. Each time the subject erred, the computer subtracted 1.0 second, down to a minimum of 1.0-second delay. Four measures were derived from this task: accuracy, longest delay achieved, mean delay, and mean response time (time for subject to decide and press the screen).
Matching Familiar Figures (MFF) task:
The MFF task is said to measure the subject's ability to pause and reflect on a complex problem, but the task clearly also tests the ability to perceive minor differences between stimuli (Aman 1991; Kagan 1965) . In our version of the MFF task, a probe stimulus was presented at the center-top of the screen, and four test stimuli were simultaneously presented across the bottom of the screen. All of the figures were drawn to be quite similar, but only one of the four stimuli at the bottom was identical to the one at the top. The child's task was to find the test stimulus that matched the probe and to push the button corresponding to that stimulus. Two variables were collected, namely, accuracy (percent correct) and response time.
Continuous Performance Task (CPT):
The CPT used in this study employed two pictures, one of a princess and one of a witch (Aman 1991) . The child was told to warn the princess by pressing a lever when the witch appeared and to refrain from responding when the princess appeared on the screen. This test of attention span took about 8 minutes to complete. There were 162 trials in all, 40 of which were the target (i.e., witch). The variables included failures to detect the witch (omission errors), incorrect detections when the princess was displayed (commission errors), and mean response time. 4. Seat Movement: The chair on which children sat was equipped with a pivot at its center and a microswitch under each of the sides (Aman 1991) . Each tilt of the seat resulted in closure of one of the microswitches, which was automatically recorded by the computer. Only activity occurring during the constant (computer-controlled) portions of the test was recorded. All tests listed here have been described much more fully in Aman (1991) .
Data analysis
Prior to inferential analyses, the data were examined for the presence of outliers and deviations from normality. The data screening occurred in a two-step process. First, extreme values (defined by SPSS [Statistical Package for the Social Sciences, Version 9.0, computer software, Chicago SPSS, 1998 ] as 3 times the interquartile range-the distance between the first quartile [25th percentile] and third quartile [75th percentile]) were identified for each variable and then excluded. Next, data were checked for degree of skew. When skewed, data were transformed using a square root, logarithmic, or inverse transformation, depending on the degree of skew (criteria: skew < 0.8, no transformation; skew 0.8-1.5, square root; skew 1.5-3.0, logarithmic; skew > 3.0, inverse). The type of transformation, if present, is presented after each variable (S = square root, L = logarithmic, I = inverse). All such transformations were performed and outliers removed before any data analyses were conducted.
For the main analysis, we used an analysis of variance (ANOVA) model, and we assessed for the effects of (a) study (1, 2, or 3; between-subjects factor) and (b) drug (placebo vs. MPH; within-subject factor). We also conducted secondary analyses to see if IQ or mental age had significant effects on outcome. For these analyses, we used a three-way ANOVA model and analyzed as a function of (a) either IQ (greater than/less than 50) or mental age (greater than/less than 4.5 years) (between subjects), (b) study, and (c) drug.
Results
Because of the number of variables assessed, we set alpha at p = 0.01. Because there are so few reports on stimulant effects in children with mental retardation, we identified changes at the 0.05 level of significance to enable readers to make exploratory comparisons (see Tables 1 and 3) .
Behavioral changes
Results for the teacher and parent ratings are presented in Table 1 . In general, subscales assessing attention problems and motor excess showed a significant advantage for MPH over placebo. There were only two minor exceptions (no effect for attention problem on the RBPC and parent CASQ). Although MPH was only given once a day, both teachers and parents were reliable in detecting differences between drug and placebo.
We derived a definition of responder by using teacher ratings on the CASQ to calculate response rate. We did this by calculating the number of children to show improvement in 10% increments using the following formula: (Placebo 2 MPH)/Placebo. Table 2 shows the rates of clinical response for various criteria (20% improvement, 30% improvement, etc.). If we arbitrarily classify children who showed more than 30% improvement as responders, then 36 of 81 children (45%) were responders. Another way to gauge change is to examine effect sizes, which were calculated for significant subscales related to inattention or overactivity. For teachers, the effect sizes were: CTRS Inattention, 0.46; CTRS Hyperactivity, 0.69; CASQ, 0.56; and ABC Hyperactivity, 0.58 (mean = 0.57). For parents, the effect sizes were usually smaller: RBPC Motor Excess, 0.26; ABC Hyperactivity, 0.35; and Global Rating, 0.56 (mean = 0.39).
Results from the cognitive tests are presented in Table 3 . All significant changes (6 of 13; 46%) indicated improvement with MPH. On the MTS task, subjects had greater accuracy and shorter response times with MPH. On the CPT, both errors of omission and errors of commission were greatly reduced (by 40.0% and 49.6%, respectively); response time was significantly reduced as well. Seat movement was significantly reduced only during the CPT (by 33.6%).
Cardiovascular changes
Heart rate was increased with MPH (3.9 beats/minute); the increases in diastolic and systolic blood pressure just failed to reach the 0.01 level of significance (2.9 and 2.1 mm Hg, respectively).
Secondary analyses: Subject variables associated with clinical response
In an effort to determine if there were useful subject variables that helped to predict clinical outcome, we divided the subjects by mental age (<4.49 or ≥4.50 years) and by IQ (<49 or ≥50). These division points were chosen because they were very close to the median T normal-ability children (Arnold 2000; Barkley 1998; Greenhill et al. 2001; The MTA Cooperative Group 1999) , although the dosage difference may account for some of the difference in response. The effect sizes observed here (mean Cohen's d of 0.57 for teachers and 0.39 for parents) were clearly smaller than those seen in typically developing children (usually at least 0.80 and 0.70 for teachers and parents, respectively). For instance, the MTA Cooperative Group (Greenhill et al. 2001) , in the placebo-controlled titration of 270 children, found effect sizes of 0.9 for teacher and 0.8 for parent ratings. Our standardized dose of 0.4 mg/kg given once daily was clearly below average doses used in typically developing children with ADHD (Arnold 2000; The MTA Cooperative Group 1999) , and it may have been suboptimal for many participants. Nevertheless, parents were able to detect MPH's effects, despite the fact that the drug was given only in the morning and although only minor drug effects may have been visible after the school day. It is quite possible that MPH (as well as other drugs) may have to be given in more conservative doses in patients with developmental disabilities, as suggested elsewhere (Arnold et al. 1998 ). Handen and associates found high rates of side effects (e.g., dysphoria, tics, lack of social responsiveness) in such children, especially with 0.6 mg/kg, the higher of two doses used (Handen et al. 1991; 2000) . In one study, medication needed to be discontinued for 6 of 27 children (22%) with developmental disabilities because of motor tics or severe social withdrawal; 2 children with social withdrawal were not exposed to the larger of two planned MPH doses (0.3 and 0.6 mg/kg), and the higher dose needed to be discontinued for another child who developed severe irritability (Handen et al. 1991) . In a study of 11 preschoolers with developmental disabilities, 5 of 10 children (50%) experienced serious side effects (primarily irritability and social withdrawal) at the 0.6-mg/kg MPH dose (0.3 and 0.6 mg/kg were used) (Handen et al. 1999 ). The higher dose was not given to an additional child who experienced irritability, crying, and anxiety at 0.3 mg/kg. Furthermore, although our doses were conservative, they were also internally consistent across all children assessed here. Thus, the more heterogeneous response in the lower IQ children cannot be considered to be merely a vagary of the dosing procedure.
Whereas IQ less than 50 was associated with a more heterogeneous response than found in higher-functioning children, we do not feel that this should preclude clinical trials in lower-functioning children. With the exception of one child with PDD-NOS who began to bite his wrist while taking MPH , we can recall no other child who showed severe side effects with the drug at this low dose. Hence, psychostimulants are often still worth a try in such youngsters, starting with a low dose and titrating cautiously.
Effects on cognitive-motor variables
The pattern we observed here was very much in keeping with what has been found in typically developing ADHD children, with the greatest effects observed in attentional variables (Aman 1978; Barkley et al. 1999; Douglas and Peters 1979) and in motor activity (Barkley 1998; Sleator 1973, 1977; Werry and Aman 1975) . Thus, the mechanism of change appears to be quite consistent regardless of clinical group. However, it is interesting that the significant decreases in seat activity were confined to the CPT, suggesting considerable task specificity in motor overflow.
Factors associated with drug response
As noted earlier, higher IQ and (for some variables) higher mental age were sometimes associated with a better drug response. This is consistent with one hypothesis that attentional variables may moderate clinical response for some children (Aman 1982 (Aman , 1996 Aman and Langworthy 2000) . However, other explanations may account for these associations better, and not all attempts to predict outcome by reference to IQ have observed a relation (e.g., Handen et al. 1994; Mayes et al. 1994) .
Conclusions
To sum up, it is clear that MPH is effective in children with low IQ and ADHD symptoms, especially with IQ down to 50. At the same time, stimulants do not appear to work as well in such children as in children with normal IQ and ADHD. This may be reflected both in the number of responders and in the magnitude of response. In a review of the mental retardation and developmental disabilities literature (Aman 1996) , an overall response rate of 54% was found. Although this may not be as good as the frequently cited figure of 65-75% for children with normal IQ, this is still a reasonable probability of response with a drug that has relatively few side effects.
The observation that psychostimulants were less successful in patients with lower mental age and IQs of below 50 may be consistent with a lower rate of response in preschoolers with ADHD (Arnold 2002) . By definition, preschoolers have lower mental ages than school-age children. Nevertheless, even in children with low IQ/low mental age, psychostimulants (because of their favorable side-effect profile) are still worth serious consideration in children with prominent ADHD. However, clinicians may wish to employ lower test doses in certain cases considered to be at high risk (e.g., those with severe self-injury, stereotypic behavior, or severe autism).
